Literature DB >> 3759251

[Calculated initial chemotherapy in mechanically-ventilated postoperative patients with peritonitis, sepsis and pneumonia].

G Hünefeld, H Weissbrodt, H Aebert, H Bunzendahl.   

Abstract

Calculated chemotherapy is based on the knowledge of the typical bacterial agents of a particular infection. From January 1983 to August 1985 bacteriological findings from surgical patients with peritonitis, septicemia or pneumonia treated in an intensive care unit were analysed. The study concentrated on those findings only which differed from previous bacteriological investigations. During the first three days 53 patients on assisted ventilation suffering from peritonitis exhibited mainly enterobacteria in their peritoneal secretions. At day 10 or later we also found bacteria from the pseudomonas group. At that time the bacterial spectrum of bronchial secretions was comparable to that of the peritoneal secretions of the same patient. After day 10, the bacterial spectrum was similar in 36 ventilated patients without peritonitis, in 56 patients suffering from post-operative pneumonia and in peritonitis patients. According to our findings, calculated chemotherapy may be based on the fact that patients with peritonitis who cannot be cured within a few days have a bacterial flora comparable to that of patients with septicemia or pneumonia. Patients with severe infections following surgery, such as potentially fatal pneumonia, generalised peritonitis or septicemia were treated with imipenem/cilastatin, according to the above definitions of calculated chemotherapy. 37 of 46 patients treated between May and December 1985, were clinically cured. Microorganisms persisted in five clinically cured patients. Development of resistance to imipenem was observed in one case. In one case treatment had to be stopped because of an allergic skin reaction. Monotherapy of peritonitis by imipenem/cilastatin appeared more satisfactory than treatment with combinations of other antibiotics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3759251     DOI: 10.1007/bf01647503

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  15 in total

1.  [Significance of the causative agent of infection for therapy of purulent peritonitis].

Authors:  D H Wittmann; W Teichmann; L Frommelt
Journal:  Chirurg       Date:  1985-06       Impact factor: 0.955

2.  Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolin.

Authors:  G B Calandra; F M Ricci; C Wang; K R Brown
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

3.  A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.

Authors:  G B Calandra; M Hesney; C Grad
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

4.  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

5.  Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group.

Authors: 
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

6.  Imipenem versus moxalactam in the treatment of serious infections.

Authors:  L J Eron; D L Hixon; C H Park; R I Goldenberg; D M Poretz
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

Review 7.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

8.  Imipenem (N-formimidoyl thienamycin): in vitro antimicrobial activity and beta-lactamase stability.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; R Kundargi
Journal:  Diagn Microbiol Infect Dis       Date:  1985-03       Impact factor: 2.803

9.  Impact of imipenem/cilastatin therapy on faecal flora.

Authors:  C E Nord; L Kager; A Philipson; G Stiernstedt
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

10.  Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.

Authors:  E D O'Donnell; E H Freimer; G L Gilardi; R Raeder
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

View more
  1 in total

1.  Paranasal sinusitis and sepsis in ICU patients with nasotracheal intubation.

Authors:  H Aebert; G Hünefeld; G Regel
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.